- Home
- XERS vs KRP Comparison
XERS vs KRP Comparison
Compare XERS & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | KRP |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XERS | KRP |
|---|---|---|
| Price | $7.67 | $14.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.83 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 1.4M | 908.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 10.25% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $333,830,000.00 |
| Revenue This Year | $34.37 | $6.88 |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | 7.93 |
| 52 Week Low | $5.25 | $11.31 |
| 52 Week High | $10.08 | $15.80 |
Technical Indicators
Market Signals| Indicator | XERS | KRP |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 48.58 |
| Support Level | $7.06 | $14.74 |
| Resistance Level | $8.95 | $15.11 |
| Average True Range (ATR) | 0.33 | 0.23 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 6.04 | 38.05 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About KRP Kimbell Royalty Partners
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.